Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: Efficacy, safety and cognitive function

European Psychiatry

Volumn 22, Issue 6, 2007, Pages 395-403

  Rainer, M ^a   Haushofer, M ^a   Pfolz, H ^b   Struhal, C ^c   Wick, W ^d  

^a DANUBE HOSPITAL   (Austria)

^b OTTO WAGNER HOSPITAL   (Austria)

^c Psychiatric and Neurological Practice   (Austria)

^d Neurology Practice   (Austria)

Author keywords

BPSD; Cognition; Dementia; Elderly; Quetiapine; Risperidone

Indexed keywords

OXAZEPAM; PROTHIPENDYL; QUETIAPINE; RISPERIDONE; ZOLPIDEM;

ADULT; AGED; AGITATION; ARTICLE; ASTHENIA; BEHAVIOR DISORDER; CEREBROVASCULAR DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; FEMUR FRACTURE; FOLLOW UP; HUMAN; INCIDENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; MOOD DISORDER; MULTICENTER STUDY; MUSCLE RIGIDITY; PERCEPTION DISORDER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SYMPTOM; THOUGHT DISORDER; URINE INCONTINENCE;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DEMENTIA; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MENTAL STATUS SCHEDULE; MIDDLE AGED; MOOD DISORDERS; NEUROPSYCHOLOGICAL TESTS; PERCEPTUAL DISORDERS; RISPERIDONE; SINGLE-BLIND METHOD; THINKING; TREATMENT OUTCOME;

EID: 34548565620     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2007.03.001     Document Type: Article

References (50)

1. Ballard C., Gray A., and Ayre G. Psychotic symptoms, aggression and restlessness in dementia. Rev Neurol (Paris) 155 Suppl 4 (1999) S44-S52
2. Ballard C., Margallo-Lana M., Juszczak E., Douglas S., Swann A., Thomas A., et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 330 (2005) 874
3. Berger G., Bernhardt T., Weimer E., Peters J., Kratzsch T., and Frolich L. Longitudinal study on the relationship between symptomatology of dementia and levels of subjective burden and depression among family caregivers in memory clinic patients. J Geriatr Psychiatry Neurol 18 (2005) 119-128
4. Brodaty H., Ames D., Snowdon J., Woodward M., Kirwan J., Clarnette R., et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 64 (2003) 134-143
5. Brodaty H., Draper B., Saab D., Low L.F., Richards V., Paton H., et al. Psychosis, depression and behavioural disturbances in Sydney nursing home residents: prevalence and predictors. Int J Geriatr Psychiatry 16 (2001) 504-512
6. Bullock R. Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings. Curr Med Res Opin 21 (2005) 1-10
7. Caligiuri M.R., Jeste D.V., and Lacro J.P. Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 17 (2000) 363-384
8. Carson S., McDonagh M.S., and Peterson K. A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. J Am Geriatr Soc 54 (2006) 354-361
9. Chan W.C., Lam L.C., Choy C.N., Leung V.P., Li S.W., and Chiu H.F. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 16 (2001) 1156-1162
10. Cummings J.L. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 48 (1997) S10-S16
11. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., and Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 (1994) 2308-2314
12. Dahlke F., Lohaus A., and Gutzmann H. Reliability and clinical concepts underlying global judgments in dementia: implications for clinical research. Psychopharmacol Bull 28 (1992) 425-432
13. De Deyn P.P., Rabheru K., Rasmussen A., Bocksberger J.P., Dautzenberg P.L., Eriksson S., et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 53 (1999) 946-955
14. Ellingrod V.L., Schultz S.K., Ekstam-Smith K., Kutscher E., Turvey C., and Arndt S. Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. Pharmacotherapy 22 (2002) 1-5
15. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., et al. Global prevalence of dementia: a Delphi consensus study. Lancet 366 (2005) 2112-2117
16. Finkel S. Introduction to behavioural and psychological symptoms of dementia (BPSD). Int J Geriatr Psychiatry 15 Suppl 1 (2000) S2-S4
17. Finkel S., Kozma C., Long S., Greenspan A., Mahmoud R., Baser O., et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr 17 (2005) 617-629
18. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
19. Fujikawa T., Takahashi T., Kinoshita A., Kajiyama H., Kurata A., Yamashita H., et al. Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type. Neuropsychobiology 49 (2004) 201-204
20. Gatterer G., Fischer P., Simanyi M., and Danielczyk W. The A-K-T ("Alters-Konzentrations-Test") a new psychometric test for geriatric patients. Funct Neurol 4 (1989) 273-276
21. Goldberg R.J. Long-term use of risperidone for the treatment of dementia-related behavioral disturbances in a nursing home population. Int J Geriatr Psychopharmacol 2 (1999) 1-4
22. Jellinger K.A. Clinicopathological analysis of dementia disorders in the elderly-An update. J Alzheimers Dis 9 (2006) 61-70
23. Jeste D.V., Rockwell E., Harris M.J., Lohr J.B., and Lacro J. Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry 7 (1999) 70-76
24. Katz I.R., Jeste D.V., Mintzer J.E., Clyde C., Napolitano J., Brecher M., et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 60 (1999) 107-115
25. Koss E., Weiner M., Ernesto C., Cohen-Mansfield J., Ferris S.H., Grundman M., et al. Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 Suppl 2 (1997) S45-S50
26. Lawlor B. Managing behavioural and psychological symptoms in dementia. Br J Psychiatry 181 (2002) 463-465
27. Lee P.E., Gill S.S., Freedman M., Bronskill S.E., Hillmer M.P., and Rochon P.A. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 329 (2004) 75
28. Livingston G., Walker A.E., Katona C.L., and Cooper C. Antipsychotics and cognitive decline in Alzheimer's disease: The LASER-AD longitudinal study. J Neurol Neurosurg Psychiatry (2006)
29. Lobo A., Launer L.J., Fratiglioni L., Andersen K., Di Carlo A., Breteler M.M., et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54 (2000) S4-S9
30. Margallo-Lana M., Swann A., O'Brien J., Fairbairn A., Reichelt K., Potkins D., et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 16 (2001) 39-44
31. McKeith I., and Cummings J. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol 4 (2005) 735-742
32. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
33. McShane R., Keene J., Gedling K., Fairburn C., Jacoby R., and Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ 314 (1997) 266-270
34. Mintzer J, Zhong K, Tariot P, Minkwitz M, Devine NA. Quetiapine in the treatment of agitation in Alzheimer's disease patients. Poster presented at the 36th Annual Meeting of the American Society of Consultant Pharmacists (ASCP), Boston, MA, USA, 9-12 November, 2005.
35. Rainer M.K., Kruger-Rainer C., Haushofer M., and Mucke H.A. Zotepine for behavioural and psychological symptoms in dementia: an open-label study. CNS Drugs 18 (2004) 1165
36. Rainer M.K., Masching A.J., Ertl M.G., Kraxberger E., and Haushofer M. Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia. J Clin Psychiatry 62 (2001) 894-900
37. Rojas-Fernandez C.H., Lanctot K.L., Allen D.D., and MacKnight C. Pharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm?. Pharmacotherapy 21 (2001) 74-102
38. Schneider L.S., Dagerman K.S., and Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294 (2005) 1934-1943
39. Schneider L.S., Pollock V.E., and Lyness S.A. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 38 (1990) 553-563
40. Schneider L.S., Tariot P.N., Dagerman K.S., Davis S.M., Hsiao J.K., Ismail M.S., et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355 (2006) 1525-1538
41. Schneider LS, Tariot P, Mintzer J, Minkwitz MC, Zhong K. Risks for cerebrovascular adverse events: use of quetiapine in patients with dementia. Poster presented at the 158th Annual Meeting of the American Psychiatric Association, Atlanta, GA, USA, 21-26 May, 2005.
42. Sink K.M., Holden K.F., and Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 293 (2005) 596-608
43. Street J.S., Clark W.S., Gannon K.S., Cummings J.L., Bymaster F.P., Tamura R.N., et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities. A double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 57 (2000) 968-976
44. Street J.S., Clark W.S., Kadam D.L., Mitan S.J., Juliar B.E., Feldman P.D., et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. Int J Geriatr Psychiatry 16 Suppl 1 (2001) S62-S70
45. Tariot P.N., Salzman C., Yeung P.P., Pultz J., and Rak I.W. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther 22 (2000) 1068-1084
46. Wancata J., Musalek M., Alexandrowicz R., and Krautgartner M. Number of dementia sufferers in Europe between the years 2000 and 2050. Eur Psychiatry 18 (2003) 306-313
47. Wimo A., Winblad B., Aguero-Torres H., and von Strauss E. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 17 (2003) 63-67
48. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. Can Med Assoc J 167 (2002) 1269-1270
49. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. Can Med Assoc J 170 (2004) 1395
50. Zhong K., Tariot P., Minkwitz M., Devine N., and Mintzer J. Quetiapine in the treatment of agitation in patients with Alzheimer's disease. J Am Geriatr Soc 53 Suppl 1 (2005) S27 abstr A26